NasdaqHealth CareHealth Care TechnologyS&P SmallCap 600
$12.05
-0.13 (-1.07%)
Close of Nov 06, 2026 · end-of-day data
CERT 8-K filings in 2026
Every material Form 8-K Certara filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Certara reported third-quarter 2026 revenue of $94.9 million, up 4% from a year earlier, with software revenue up 11% and services revenue down 2%. The net loss from continuing operations narrowed to $3.6 million, and the company narrowed its full-year 2026 revenue growth range to 2% to 3% and updated its adjusted diluted EPS range to $0.31 to $0.34.
Q3 2026 revenue $94.9 million vs. $90.9 million in Q3 2025; software revenue $48.8 million (up 11%), services revenue $46.1 million (down 2%)
Net loss from continuing operations $3.6 million vs. $4.8 million a year earlier; adjusted EBITDA $30.2 million, up 6%
2026 full-year revenue growth range narrowed to 2% to 3%; adjusted diluted EPS outlook $0.31 to $0.34
Grant Peterson appointed Chief Product Officer, effective November 2, 2026
Certara reported second-quarter 2026 revenue of $93.3 million, up 1% from a year earlier, but swung to a continuing-operations net loss of $6.1 million from a $1.5 million profit. Total net loss attributable to common stockholders was $55.3 million, including a $49.2 million loss from discontinued operations tied to the divested Regulatory and Medical Writing business. The company reaffirmed its 2026 revenue growth guidance of 0% to 4%, while shareholders also received updated adjusted EBITDA margin and adjusted EPS guidance.
Software revenue rose 4% to $48.8 million, while services revenue fell 3% to $44.5 million.
Adjusted EBITDA was $26.2 million, down from $27.0 million; diluted loss per share from continuing operations was $(0.04) versus $0.01 a year earlier.
The company completed a $100 million share repurchase program and the board approved an additional $50 million.
Julien Perrier was appointed Chief Commercial Officer effective August 1, 2026.
Certara, Inc. said its President and Chief Commercial Officer, Leif E. Pedersen, left that role effective August 1, 2026. He will stay on as a Senior Advisor to help with transition matters until December 31, 2026, when his employment is set to end without cause and he becomes eligible for severance under his existing agreement and the company's Executive Officer Severance Policy.
Departure from President and Chief Commercial Officer role effective August 1, 2026
Senior Advisor role for transition matters through December 31, 2026
Employment to be terminated without cause on December 31, 2026, with severance benefits
Severance details are incorporated by reference from the April 3, 2026 proxy statement
Certara, Inc. said Chief Financial Officer John E. Gallagher III will resign to pursue another opportunity, with his last day expected July 14, 2026. Faiz Mohammed, the company's Senior Vice President, Finance and Treasurer since 2018, will serve as interim CFO and principal financial and accounting officer, and the company has started a search for a successor. The company also reaffirmed its 2026 financial guidance, and the filing states the resignation was not due to any disagreement with management, the board, or financial reporting matters.
CFO John E. Gallagher III tendered his resignation on June 11, 2026; he is expected to serve through July 14, 2026.
Faiz Mohammed, age 53, will become interim CFO effective July 15, 2026, and has been SVP, Finance and Treasurer since 2018.
Company reaffirmed 2026 financial guidance first given on the May 11, 2026 first-quarter earnings call.
Gallagher is expected to help with the closing process for the quarter ending June 30, 2026.
Certara reported first-quarter 2026 revenue of $106.9 million, up 1% from a year earlier, but swung to a net loss of $8.8 million from net income of $4.7 million. The company also completed the $85.0 million cash sale of its medical writing business to Veristat on May 8, 2026, and updated its full-year 2026 revenue guidance to reflect the divestiture.
Revenue was $106.9 million, up 1% from $106.0 million; software rose 7% to $49.7 million and services fell 4% to $57.2 million.
Net loss was $8.8 million, or $0.06 per diluted share, versus net income of $4.7 million, or $0.03 per diluted share, in Q1 2025; adjusted EBITDA fell to $31.7 million from $34.8 million.
Sale of the medical writing business to Veristat closed May 8, 2026, for $85.0 million cash, plus $15.0 million in escrow and up to $35.0 million in earn-out payments.
Full-year 2026 revenue guidance is $395 million to $405 million, including about $18 million from the divested business; adjusted diluted EPS guidance is $0.35 to $0.41.
Certara agreed on April 21, 2026 to sell its global medical writing and related regulatory services business to Veristat for $100 million in cash, plus up to $35 million in earn-out payments tied to the business's performance after closing. The company expects the sale to close in the second quarter of 2026 and plans to update its 2026 guidance at that time, so shareholders will not see the sale's full effect on guidance until then.
Cash consideration of $100 million, subject to post-closing adjustments for working capital, indebtedness and transaction expenses
Up to $35 million in contingent earn-out payments based on the business's financial performance after closing
Up to $15 million of the closing payment may be held in escrow if certain items are not satisfied at closing
The business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025; closing is expected in the second quarter of 2026
Certara director Cynthia Collins, a Class II director who also sits on the Audit Committee, notified the company on March 27, 2026 that she will resign effective May 14, 2026, the date of the 2026 annual meeting. She said the resignation is not due to any disagreement with the company on its operations, policies or practices, and the filing reports no financial results or guidance.
Cynthia Collins notified Certara on March 27, 2026 of her intent to resign as a Class II director
Resignation takes effect May 14, 2026, the date of the 2026 annual meeting of stockholders
Collins is a member of the Board and the Audit Committee
Filing states the resignation is not the result of any disagreement with the company
Certara reported fourth-quarter 2025 revenue of $103.6 million, up 3%, but swung to a net loss of $5.9 million from net income of $6.6 million a year earlier. It also guided full-year 2026 revenue growth of 0-4% and adjusted diluted EPS of $0.44-$0.48, with adjusted EPS for 2025 at $0.44. Shareholders face flat-to-modest growth guidance and lower profit, with new CEO Jon Resnick, effective January 1, 2026, describing 2026 as a year of transition and investment.
Q4 2025 revenue was $103.6 million, up 3%; software revenue rose 10% to $46.4 million and services revenue fell 1% to $57.3 million.
Q4 2025 net loss was $5.9 million, versus net income of $6.6 million in Q4 2024; adjusted diluted EPS was $0.09, versus $0.15.
Full-year 2025 revenue was $418.8 million, up 9%; full-year adjusted diluted EPS was $0.44, versus $0.45 in 2024.
2026 guidance: revenue growth of 0-4%, adjusted EBITDA margin of 30-32%, and adjusted diluted EPS of $0.44-$0.48.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Certara filing is on SEC EDGAR ↗. 8-K briefs of other companies →